Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...

Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top ...

Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...

Johnson & Johnson has secured European approval for the subcutaneous formulation of Darzalex, combined with bortezomib, lenalidomide, and dexamethasone, for newly diagnosed multiple myeloma patients ...

Shopping Win Highlights Irresistible Bankruptcy ToolJ&J’s Bankruptcy Effort Fails High Court Test, Holdouts Say J&J Unit ...

Sales of Johnson & Johnson’s oncology drugs jumped nearly 19% in the third quarter, driven by cancer treatment Darzalex which ...

Janssen-Cilag’s Darzalex -SC based quadruplet regimen gets European approval to treat patients with newly diagnosed MM who are transplant-eligible: Beerse, Belgium Thursday, Oct ...

Analyst Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...

Johnson & Johnson (J&J) raised its 2024 profit and sales forecasts on October 15, thanks to strong sales of oncology drugs, ...

Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...

Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and ...

co-formulation patents for DARZALEX ® (daratumumab) SC (Patent EP 3827845). "While we are disappointed with the EPO's ...